Old Web
English
Sign In
Acemap
>
authorDetail
>
Masanori Yamada
Masanori Yamada
GlaxoSmithKline
Medicine
Pharmacokinetics
B-cell activating factor
Belimumab
Lupus erythematosus
4
Papers
7
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?
2021
Clinical pharmacology in drug development
Masaru Hirano
Masanori Yamada
Toshiaki Tanaka
Toshiko Koue
Tomohisa Saito
Mitsuo Higashimori
Hisao Ochiai
Junichi Yamamoto
Saori Yaguchi
S. Mita
Katsutoshi Hara
PD Task Force
Show All
Source
Cite
Save
Citations (0)
A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat.
2020
Clinical pharmacology in drug development
Masanori Yamada
Minori Osamura
Hirofumi Ogura
Tomohiro Onoue
Akira Wakamatsu
Yotaro Numachi
Stephen Caltabiano
Kelly M. Mahar
Show All
Source
Cite
Save
Citations (1)
Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
2013
Journal of drug assessment
Masanori Yamada
Mikio Akita
Tomofumi Nakagawa
Naoki Takahashi
Akira Endo
Pascal Yoshida
Show All
Source
Cite
Save
Citations (6)
Original Article Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
2013
Masanori Yamada
Mikio Akita
Tomofumi Nakagawa
Naoki Takahashi
Show All
Source
Cite
Save
Citations (0)
1